Supportive Care for Breast Cancer Patients Taking Tamoxifen

30-50% of breast cancer patients stop taking their tamoxifen therapy early.

Breast cancer affects one in every eight American women. Join Dr. Nancy Peacock, Medical Oncologist specializing in breast cancer treatment (at Tennessee Oncology and Tri-Star Centennial Medical Center, Nashville) for an in-depth and frank discussion of the issues related to Oncology Supportive Care. Learn why certain long-term breast cancer therapy treatments are so vital to the ultimate success in managing the disease that affects women of all ages.


The Balancing Act


A New Option for Breast Cancer Patients

Now there is a new option for breast cancer patients taking tamoxifen… and treatment for battling mouth ulcers.

Breast cancer: The sobering statistics are that approximately one in eight American women will develop breast cancer during their lifetime. Breast cancer is the second most commonly diagnosed form of cancer in women and chances are you will know someone who will be touched by it or possibly experience breast cancer yourself.

Breast cancer requires patients complete a complex treatment regimen. That’s why it’s important for physicians and patients to discuss treatment options, choices and educational information to ensure patients and their families can make informed decisions about their care.

There is now a choice when it comes to tamoxifen therapy. Tamoxifen is a widely used treatment for certain forms of breast cancer but patients do not always take the medication as they should, putting them at increased risk for reoccurrence. Clinicians and patients should discuss the importance of staying on their tamoxifen long term, and treatment options which can help support this goal.

Soltamox® (tamoxifen citrate) oral solution is the only FDA approved liquid form of tamoxifen and can be an effective option to help patients When offered a choice, patients who prefer or need a liquid form of tamoxifen (due to physiological or psychological difficulties) may stay on treatment better.

– Did you know that 30-50% of breast cancer patients stop taking their tamoxifen therapy early?

During cancer treatment, chemotherapy and radiation therapy often cause unwanted side effects, including a condition called oral mucositis, which results in painful mouth sores and ulcers. Oral mucositis also can affect a patient’s ability to eat and drink and may result in interruption of their cancer treatment.

Options to treat the symptoms of oral mucositis exist and should be given early. These include traditional pain medications, as well as Gelclair®, an oral rinse gel that can alleviate pain by covering exposed nerve endings in the mouth. Reducing pain improves patients’ ability to swallow food and liquids, helping to maintain good nutritional status and reducing the risk of cancer treatment interruption.

– Did you know that oral mucositis occurs in about 40% all patients treated for cancer and in up to 100% of patients treated for head and neck cancer?

“DARA BioSciences Inc. is pleased to partner with The Balancing Act, to produce this educational segment about breast cancer treatment and support, and appreciates The Balancing Act’s commitment to breast cancer education and programming during Breast Cancer Awareness Month” said David J.Drutz, MD DARA’s chief executive officer and chief medical officer. “We are grateful to Dr. Peacock and Ms. Megee for sharing their experiences on national television, so that others may learn from their insights and knowledge”.

To learn more about this important topic, tune in to the educational segment “A New Option for Breast Cancer Patients Taking Tamoxifen” sponsored by DARA Biosciences Inc. on Monday, October 14th and Monday October 21st at 7:00 am (ET/PT). Nancy Peacock, M.D., Medical Oncologist at Tennessee Oncology and Julie McGee, Breast Cancer Survivor join the show as part of The Balancing Act on Lifetime TV’s Breast Cancer Awareness programming to discuss oncology supportive care.

Tamoxifen Important Safety Information
Serious and life-threatening events associated with tamoxifen medications such as Soltamox (tamoxifen citrate) in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. Some of the strokes, pulmonary emboli, and uterine malignancies were fatal. Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.

WARNING
In Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer Serious and life-threatening events were associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. (See CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High Risk Women). Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.

Please visit http://www.soltamox.com for the full Prescribing Information and complete Black Box Warning.

Gelclair® Important Safety Information
Do not use Gelclair® if there is a known or suspected hypersensitivity to any of its ingredients. No adverse effects have been reported in clinical trials, although post marketing reports have included infrequent complaints of burning sensation in the mouth. While Gelclair® should not be swallowed, no adverse effects are anticipated.
Please visit http://www.Gelclair.com for the full Prescribing Information.


New Options for Breast Cancer Patients on The Balancing Act® airing on Lifetime TV

FOR IMMEDIATE RELEASE

Media Contact:
O2 Media, Inc.
pamela@o2mediainc.com
(954) 691-1102

The Balancing Act® airing on Lifetime TV Talks New Options for Breast Cancer Patients

Breast Cancer Awareness Month Programming Features DARA BioSciences Inc. and New York Breast Reconstruction Alliance hosted by Julie Moran on October 14th Show

(Pompano Beach, FL – PR.Com/CISION – October 9, 2013) Popular morning show The Balancing Act® airing on Lifetime TV welcomes two companies dedicated to providing new options for breast cancer patients to the show airing on Monday, October 14 at 7:00 a.m. (ET/PT) as part of Breast Cancer Awareness Month Programming. Make sure to tune in as The Balancing Act hosts help jump start the day with animated conversation and trusted information to empower a woman’s life.

Don’t miss these featured segments taking center stage on The Balancing Act®:

– Breast Reconstruction: What You Need to Know with New York Breast Reconstruction Alliance
The fact is that 7 out of 10 women in this country are not even aware that breast reconstruction exists is an option, with only 20% of women who undergo mastectomy going on to have reconstruction. And the good news is that breast reconstruction is covered by most health insurance plans. Join Dr. Randall Feingold, Plastic Surgeon and Founder of the New York Breast Reconstruction Alliance, as he discusses the latest groundbreaking techniques in breast reconstruction and comprehensive resources available for education and patient care for women and their families. Also joining the show is Kim Dresch, a breast cancer survivor who shares her inspiring story and advocacy efforts. http://www.nybra.com
http://www.breastreconstruction.org

– New Options for Breast Cancer Patients, supported by DARA BioSciences Inc.
Breast cancer: Approximately one in eight American women will develop breast cancer during their lifetime, so chances are you know someone who has been touched by the disease or possibly experience breast cancer yourself. Join Nancy Peacock, MD, a breast cancer specialist from Tennessee Oncology, and Julie Megee, breast cancer survivor, for an in-depth discussion regarding the importance of patient compliance to tamoxifen therapy and how Soltamox® (tamoxifen citrate) oral solution may help compliance in patients who prefer or need a liquid formulation. The guests also discuss other supportive care issues, including how the painful symptoms of oral mucositis caused by radiation treatment and chemotherapy may be relieved by Gelclair®, an oral rinse gel, as well as the role of Bionect® topical ointment in helping to alleviate radiation-induced skin irritation and burns.

This educational segment on breast cancer is sponsored by DARA BioSciences, an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment. DARA holds US marketing rights to Soltamox®, the only FDA-approved liquid form of tamoxifen, which is widely used for the treatment and prevention of breast cancer. The company also markets Gelclair®, a bioadherent oral rinse gel for relief of oral mucositis pain caused by chemotherapy and radiation treatment, and Bionect® (hyaluronic acid sodium salt, 0.2%), a topical treatment for skin irritation and burns, in US oncology/radiology markets.

Please see Soltamox® (tamoxifen citrate) Important Safety Information and the Black Box Warning, below. For full Prescribing Information and the complete Black Box warning visit http://www.soltamox.com.

For additional information on DARA BioSciences and its products visit http://www.Darabio.com, http://www.Gelcliar.com http://www.Soltamox.com and http://www.bionect.com.

“We are pleased to partner with The Balancing Act® to produce this educational segment about breast cancer treatment and support, and appreciate The Balancing Act’s commitment to breast cancer education and programming during Breast Cancer Awareness Month,” said David J. Drutz, MD, DARA’s chief executive officer and chief medical officer. “We are grateful to Dr. Peacock and Ms. Megee for sharing their experiences on national television, so that others may learn from their insights and knowledge.”
IMPORTANT SAFETY INFORMATION
Tamoxifen citrate is contraindicated in patients with known hypersensitivity and also in women who require concomitant coumarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. If hypercalcemia does occur, appropriate measures should be taken and, if severe, tamoxifen should be discontinued. There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy. When tamoxifen is coadministered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. Adverse reactions to tamoxifen are relatively mild and rarely severe enough to require discontinuation of treatment in breast cancer patients.
WARNING
In Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer Serious and life-threatening events were associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. (see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer Incidence In High Risk Women). Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen to reduce their risk of developing breast cancer. The benefits of tamoxifen outweigh its risks in women already diagnosed with breast cancer.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-855-273 0468

About The Balancing Act® on Lifetime Television
Now in its 6th year, The Balancing Act® continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple – the show strives to help today’s modern woman balance it all by bringing them exceptional solutions to everyday problems. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings at 7:00 am (ET/PT) on Lifetime television.

For additional information or to view a segment visit: http://www.thebalancingact.com
Join the Conversation!
Like us on Facebook at: https://www.facebook.com/TheBalancingActFans
Follow us on Twitter at: http://twitter.com/#!/balancingacttv
Watch us on YouTube at: http://www.youtube.com/thebalancingact